Trial Profile
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Sugemalimab (Primary)
- Indications T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms GEMSTONE-201
- Sponsors CStone Pharmaceuticals
- 13 Jun 2023 According to a CStone Pharmaceuticals media release, The supplemental biologics license applications for sugemalimab for the treatment of patients with relapsed/refractory extranodal NK/T-cell lymphoma, as well as in combination with chemotherapy for first-line treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma, and in combination with chemotherapy for first-line treatment of unresectable locally advanced, recurrent, or metastatic ESCC have been accepted
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2023 Results published in the CStone Pharmaceuticals Media Release.